Back

Neuropsychiatric disorders as risk factors and consequences of COVID-19: A Mendelian randomization study

XIANG, Y.; QIU, J.; ZHANG, R.; CHAU, C. K.-L.; RAO, S.; SO, H.-C.

2021-07-03 infectious diseases
10.1101/2021.06.29.21259609 medRxiv
Show abstract

BackgroundMore than 180 million cases of COVID-19 have been reported worldwide. It has been proposed that neuropsychiatric disorders may be risk factors and/or consequences of COVID-19 infection. However, observational studies could be affected by confounding bias. MethodsWe performed bi-directional two-sample Mendelian randomization (MR) analysis to evaluate causal relationships between liability to COVID-19 (and severe/critical infection) and a wide range of neuropsychiatric disorders or traits. We employed GWAS summary statistics from the COVID-19 Host Genetics Initiative. A variety of MR methods including those accounting for horizontal pleiotropy were employed. ResultsOverall, we observed evidence that liability to COVID-19 or severe infection may be causally associated with higher risks of post-traumatic stress disorder (PTSD), bipolar disorder (BD) (especially BD II), schizophrenia (SCZ), attention deficit hyperactivity disorder (ADHD) and suicidal thought (ST) when compared to the general population. On the other hand, liability to a few psychiatric traits/disorders, for example ADHD, alcohol and opioid use disorders may be causally associated with higher risks of COVID-19 infection or severe disease. In genetic correlation analysis, cannabis use disorder, ADHD, and anxiety showed significant and positive genetic correlation with critical or hospitalized infection. All the above findings passed multiple testing correction at a false discovery rate (FDR)<0.05. For pneumonia, in general we observed a different pattern of causal associations. We observed bi-directional positive associations with depression- and anxiety-related phenotypes. ConclusionsIn summary, this study provides evidence for tentative bi-directional causal associations between liability to COVID-19 (and severe infection) and a number of neuropsychiatric disorders. Further replications and prospective studies are required to verify the findings.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Translational Psychiatry
219 papers in training set
Top 0.1%
49.3%
2
PLOS ONE
4510 papers in training set
Top 26%
6.5%
50% of probability mass above
3
The British Journal of Psychiatry
21 papers in training set
Top 0.2%
3.7%
4
Scientific Reports
3102 papers in training set
Top 34%
3.7%
5
Psychological Medicine
74 papers in training set
Top 0.6%
3.2%
6
Progress in Neuro-Psychopharmacology and Biological Psychiatry
36 papers in training set
Top 0.3%
2.1%
7
BMJ Open
554 papers in training set
Top 9%
1.7%
8
Addiction Biology
47 papers in training set
Top 0.5%
1.7%
9
Molecular Psychiatry
242 papers in training set
Top 3%
1.1%
10
Frontiers in Psychiatry
83 papers in training set
Top 2%
1.1%
11
Drug and Alcohol Dependence
37 papers in training set
Top 0.5%
1.0%
12
JAMA Network Open
127 papers in training set
Top 3%
0.9%
13
Schizophrenia Research
29 papers in training set
Top 0.5%
0.9%
14
Psychiatry Research
35 papers in training set
Top 1%
0.8%
15
European Journal of Neuroscience
168 papers in training set
Top 1%
0.8%
16
Brain, Behavior, & Immunity - Health
27 papers in training set
Top 0.4%
0.8%
17
American Journal of Psychiatry
20 papers in training set
Top 0.4%
0.8%
18
Acta Neuropsychiatrica
12 papers in training set
Top 0.8%
0.8%
19
BMC Medicine
163 papers in training set
Top 6%
0.8%
20
Cells
232 papers in training set
Top 6%
0.8%
21
Human Brain Mapping
295 papers in training set
Top 4%
0.8%
22
JAMA Psychiatry
13 papers in training set
Top 0.5%
0.8%
23
Frontiers in Public Health
140 papers in training set
Top 9%
0.7%
24
Journal of Clinical Medicine
91 papers in training set
Top 7%
0.7%
25
Frontiers in Pharmacology
100 papers in training set
Top 5%
0.7%